Paradigm Biopharmaceuticals (ASX:PAR) has completed enrolment for its Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for treating mucopolysaccharidosis type VI (MPS VI).

The trial aims to evaluate the safety and tolerability of iPPS in subjects with MPS VI, with secondary endpoints assessing effects on pain, functionality, and glycosaminoglycan levels.

The company already received Orphan Drug Designation status in the US and EU for MPS VI and MPS I.